These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 16227166)
21. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum]. Uchida K; Nakanishi M; Yoh K Rinsho Byori; 2001 Jan; 49(1):51-5. PubMed ID: 11215484 [TBL] [Abstract][Full Text] [Related]
22. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Rissanen JP; Suominen MI; Peng Z; Halleen JM Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692 [TBL] [Abstract][Full Text] [Related]
23. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975 [TBL] [Abstract][Full Text] [Related]
24. Tartrate-resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese. Cheng T; Wang M; Chen Z; Eisenberg RA; Zhang Y; Zou Y; Deng Y; Wang M; Zhou L Chin Med J (Engl); 2014; 127(16):2894-9. PubMed ID: 25131223 [TBL] [Abstract][Full Text] [Related]
25. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577 [TBL] [Abstract][Full Text] [Related]
26. Alternative immunoassay for tartrate-resistant acid phosphatase isoform 5b using the fluorogenic substrate naphthol ASBI-phosphate and heparin. Janckila AJ; Simons RM; Yam LT Clin Chim Acta; 2004 Sep; 347(1-2):157-67. PubMed ID: 15313154 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Capeller B; Caffier H; Sütterlin MW; Dietl J Anticancer Res; 2003; 23(2A):1011-5. PubMed ID: 12820340 [TBL] [Abstract][Full Text] [Related]
29. Specificity and clinical performance of two commercial TRACP 5b immunoassays. Ylipahkala H; Fagerlund KM; Janckila AJ; Houston B; Laurie D; Halleen JM Clin Lab; 2009; 55(5-6):223-8. PubMed ID: 19728556 [TBL] [Abstract][Full Text] [Related]
30. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696 [TBL] [Abstract][Full Text] [Related]
31. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839 [TBL] [Abstract][Full Text] [Related]
32. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156 [TBL] [Abstract][Full Text] [Related]
33. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases. Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403 [TBL] [Abstract][Full Text] [Related]
34. [Tartrate resistant acid phosphatase--TRACP-5b as a modern bone resorption marker]. Nowak Z; Konieczna M; Saracyn M; Wańkowicz Z Pol Merkur Lekarski; 2008 Apr; 24(142):351-4. PubMed ID: 18634372 [TBL] [Abstract][Full Text] [Related]
35. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501 [TBL] [Abstract][Full Text] [Related]
36. Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis. Wu YY; Janckila AJ; Ku CH; Yu CP; Yu JC; Lee SH; Liu HY; Yam LT; Chao TY BMC Cancer; 2010 Apr; 10():158. PubMed ID: 20416078 [TBL] [Abstract][Full Text] [Related]
37. Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study. Yamamichi G; Kato T; Yumiba S; Tomiyama E; Koh Y; Nakano K; Matsushita M; Hayashi Y; Ishizuya Y; Watabe T; Hatano K; Kawashima A; Ujike T; Ono Y; Takada T; Takada S; Imamura R; Nonomura N; Uemura M Int J Urol; 2023 Jan; 30(1):70-76. PubMed ID: 36305578 [TBL] [Abstract][Full Text] [Related]
38. Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay. Wu Y; Lee JW; Uy L; Abosaleem B; Gunn H; Ma M; DeSilva B J Pharm Biomed Anal; 2009 Jul; 49(5):1203-12. PubMed ID: 19356879 [TBL] [Abstract][Full Text] [Related]
39. Value of TRAcP 5b as a diagnostic marker for detection of bone metastases in patients with breast cancer. Hung MJ; Oremek GM Eur J Gynaecol Oncol; 2011; 32(6):615-8. PubMed ID: 22335021 [TBL] [Abstract][Full Text] [Related]
40. A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum. Alatalo SL; Peng Z; Janckila AJ; Kaija H; Vihko P; Vaananen HK; Halleen JM J Bone Miner Res; 2003 Jan; 18(1):134-9. PubMed ID: 12510815 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]